Evidence map›Paper›PMID 34395717›Full record

ArticleOpen forum infectious diseases2021

Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease.

Michael J Peluso, Sadie E Munter, Kara L Lynch, Cassandra Yun, Leonel Torres, Nikita S Iyer, Joanna Donatelli, Lindsay Ryan, Amelia N Deitchman, Steven G Deeks and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Michael J PelusoDivision of HIV, Infectious Disease and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Sadie E MunterDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.
Kara L LynchDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.
Cassandra YunDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-6971-2060
Leonel TorresDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.
Nikita S IyerDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.
Joanna DonatelliDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.
Lindsay RyanDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Amelia N DeitchmanDepartment of Clinical Pharmacology, University of California San Francisco, San Francisco, California, USA.
Steven G DeeksDivision of HIV, Infectious Disease and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Rachel L RutishauserDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.
Timothy J HenrichDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.
University of California, San Francisco · US

Funding

Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
NIAID NIH HHS T32 AI060530
6 · The paper itself

Abstract

We report a patient with connective tissue disease who developed modest severe acute respiratory syndrome coronavirus 2 receptor binding domain-specific antibody levels and a lack of neutralization capacity, despite having received 3 mRNA coronavirus disease 2019 vaccines and holding anti-B-cell therapy for >7 months before vaccination. The patient developed virus-specific T-cell responses.

Indexed as

COVID-19 vaccineneutralizing antibodiesrheumatological diseaseSARS-CoV-2T-cell immunity

Identifiers

PMID34395717
PMCPMC8344490
OpenAlexW3196252108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.